ECE2010 Poster Presentations Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) (125 abstracts)
Results of French collaborative evaluation (DEPHY-TC) in patients with suspected pituitary abnormalities after traumatic brain injury (TBI)
S Courtois 1 , M L Nunes 2 , M F Malezet 3 , N Morlet-Barla 4 , F Borson-Chazot 1 , P Peruzzi 3 , A Tabarin 2 , M Delarque 4 , S Ciancia 1 , F Boyer 3 , E Cuny 2 , A Delarque 4 , B Delemer 3 , E Richer 2 , H Curallucci 5 , L Di Nicola 6 & G Raverot 1
1Fédération d’endocrinologie du pole Est, Hospices Civils de Lyon, Lyon, France; 2CHU de Bordeaux, Bordeaux, France; 3CHU Robert Debré-Reims, Reims, France; 4Endocrinologie, médecine physique et réadaptation, assistance publique hopitaux de Marseille, Marseille, France; 5Etablissement de Réeducation et réadaptation fonctionnelle neurologique, clinique Saint Martin, Marseille, France; 6IPSEN Pharma SAS, Boulogne Billancourt, France.
Study aim: Pituitary function evaluation in patients with traumatic brain injury (TBI).
Subjects: One hundred and forty-six patients (49 female, 97 men, age: 31.9±16.2 years) recovered from moderate to severe TBI. Prospective follow up has been performed 3/6 and 12 months from TBI for 79 subjects. Retrospective evaluation (from 0.3 to 30 years) included 67 subjects selected in front of overt clinical features (obesity, fatigue, sexual disorders).
Methods: Clinical (neurological, endocrine, and general) and hormonal evaluations were performed using a standardized protocol including determination of FT4, TSH, PRL, IGF1, testosterone/E2, FSH and LH. Corticotrope and somatotrope axes were evaluated using glucagon-, insulin tolerance- or GHRH-arginine tests.
Results: Prospective group. 3–6 months after TBI (n=79): 44.3% presented endocrine dysfunction: GH deficiency (GHD) (22%) gonadotrope deficiency (19%), corticotrope deficiency (13%), thyrotrope deficiency (5%). Twelve months after TBI (n=46) 34.8% presented endocrine dysfunction: GH deficiency (GHD) (15%) gonadotrope deficiency (24%), corticotrope deficiency (2%), thyrotrope deficiency (2%).
Combined deficiency was observed in 12.6 and 6.5% of cases initially and after 12 months respectively.
Six of nine patients with GHD at first evaluation recovered normal somatotrope function after 12 months but three new patients with GHD were diagnosed at this time.
Retrospective group (n=67) 45.3% subjects presented endocrine dysfunction: GHD (32.8%), gonadotrope deficiency (17.1%), corticotrope deficiency (9.3%), thyrotrope deficiency (4.7%). Combined deficiency was observed in 17.1% of cases.
Among patients with a follow-up after TBI >1 year (n=99), GHD patients (n=25) presented significant increase of body mass index (P<0.05) compare to GH sufficient patients (n=74).
Conclusion: Our data in the prospective cohort confirm that pituitary dysfunction after TBI may evolve over time and requires multiple evaluations. Prospective interventions studies are needed to evaluate the benefits of hormonal supplementation in these patients.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more